Randomized controlled clinical study evaluating the efficacy and safety of intratumoral treatment of canine mast cell tumors with tigilanol tiglate (EBC‐46)
De Ridder TR, Campbell JE, Burke‐Schwarz C, Clegg D, Elliot EL, Geller S, Kozak W, Pittenger ST, Pruitt JB, Riehl J, White J, Wiest ML, Johannes CM, Morton J, Jones PD, Schmidt PF, Gordon V, Reddell P. Randomized controlled clinical study evaluating the efficacy and safety of intratumoral treatment of canine mast cell tumors with tigilanol tiglate (EBC‐46). Journal Of Veterinary Internal Medicine 2020, 35: 415-429. PMID: 32542733, PMCID: PMC7848366, DOI: 10.1111/jvim.15806.Peer-Reviewed Original ResearchConceptsMast cell tumorsComplete responseControl dogsAdverse eventsIntratumoral treatmentTigilanol tiglateCell tumorsClinical studiesTumor volumeModified Response Evaluation CriteriaTT treatmentOverall complete responseResponse Evaluation CriteriaCanine mast cell tumorsPhase 1Quality of lifeConcomitant medicationsTumor resolutionLocal treatmentTreatment responseSolid tumorsDogsTumorsTreatmentEfficacy